Amicus Therapeutics (FOLD): Revenue Loss from migalastat Drives PT Cut - Baird

November 29, 2016 7:00 AM EST Send to a Friend
Baird analyst, Michael Ulz, reiterated his Neutral rating on shares of Amicus Therapeutics (NASDAQ: FOLD) and cut his price target ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login